New US Patent Extends Argenica’s Neuroprotective Peptide Coverage to 2034
Argenica Therapeutics has expanded its intellectual property with a new US patent targeting surgically induced strokes, enhancing the commercial potential of its lead drug candidate ARG-007.
- New US patent granted for neuroprotective peptides targeting surgery-related stroke
- Patent covers high-risk cardiac and vascular operations with elevated stroke risk
- Extends protection from earlier parent patent until October 2034
- ARG-007 advancing through Phase 2 clinical trials for acute ischaemic stroke
- Top-line Phase 2 data expected in Q3 2025 could validate broader clinical use
Strengthening Patent Protection
Argenica Therapeutics Limited (ASX: AGN), a clinical-stage biotech focused on neuroprotective therapies, has secured a new US patent that specifically targets the prevention of strokes induced by surgical procedures. This divisional patent, granted by the United States Patent Office, builds upon the company’s existing intellectual property portfolio by covering the use of its neuroprotective peptides in patients undergoing high-risk surgeries, such as cardiac and vascular operations where stroke risk is notably elevated.
The newly granted patent (No. 12,303,550) extends the scope of Argenica’s earlier parent patent, which broadly protects its neuroprotective peptides against various neurological injuries including ischaemic stroke and traumatic brain injury. The divisional patent focuses on peri-operative stroke prevention, a critical complication arising from emboli during surgeries like thoracic-aortic repairs and valve replacements, where stroke rates can increase by up to 10% above baseline.
Clinical and Commercial Implications
Argenica’s lead candidate, ARG-007, is currently in Phase 2 clinical trials targeting acute ischaemic stroke patients, particularly those suffering large-vessel occlusions. The company anticipates releasing top-line data in the third quarter of 2025. Positive results could not only confirm ARG-007’s neuroprotective efficacy in stroke but also open new clinical avenues for its use in preventing surgery-related strokes, a significant unmet medical need.
Dr Liz Dallimore, Managing Director of Argenica, highlighted that this new patent strengthens the company’s competitive position by expanding the potential applications of ARG-007. The patent protection extends until October 2034, providing a substantial window for commercial development and potential partnerships or licensing opportunities.
Looking Ahead
While the patent grant marks a milestone, the ultimate commercial success of ARG-007 hinges on forthcoming clinical trial outcomes and regulatory approvals. The biotech sector will be watching closely as Argenica advances its clinical program, with the new patent serving as a strategic asset to safeguard its innovations in a competitive neurotherapeutics landscape.
Bottom Line?
Argenica’s new patent fortifies its stroke prevention strategy, setting the stage for pivotal Phase 2 results later this year.
Questions in the middle?
- Will Phase 2 trial data confirm ARG-007’s efficacy in preventing surgery-related strokes?
- How will Argenica position ARG-007 commercially if clinical results are positive?
- What competitive threats or opportunities exist in the neuroprotective peptide market?
